doi:10.1038/nature25480

Supplementary Note 1: Reference list data sources

Leukemia and lymphoma:

Andersson, A. K. *et al*. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. *Nat. Genet.* **47**, 330-337, doi:10.1038/ng.3230 (2015).

Bandapalli, O. R. *et al*. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. *Haematologica* **99**, e188-192, doi:10.3324/haematol.2014.104992 (2014).

Faber, Z. J. *et al*. The genomic landscape of core-binding factor acute myeloid leukemias. *Nat. Genet.* **48**, 1551-1556, doi:10.1038/ng.3709 (2016).

Gruber, T. A. *et al*. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. *Cancer Cell* **22**, 683-697, doi:10.1016/j.ccr.2012.10.007 (2012).

Holmfeldt, L. *et al*. The genomic landscape of hypodiploid acute lymphoblastic leukemia. *Nat. Genet.* **45**, 242-252, doi:10.1038/ng.2532 (2013).

Irving, J. *et al*. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. *Blood* **124**, 3420-3430, doi:10.1182/blood-2014-04-531871 (2014).

Kunz, J. B. *et al*. Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. *Haematologica* **100**, 1442-1450, doi:10.3324/haematol.2015.129692 (2015).

Li, B. *et al*. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. *Nat. Med.* **21**, 563-571, doi:10.1038/nm.3840 (2015).

Lopez *et al*., Borkhardt *et al*., in preparation

Ewing's sarcoma:

Agelopoulos, K. *et al*. Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. *Clin. Cancer. Res.* **21**, 4935-4946, doi:10.1158/1078-0432.ccr-14-2744 (2015).

Hepatoblastoma:

Eichenmuller, M. *et al*. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. *Journal of hepatology* **61**, 1312-1320, doi:10.1016/j.jhep.2014.08.009 (2014).

Osteosarcoma:

Chen, X. *et al*. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. *Cell reports* **7**, 104-112, doi:10.1016/j.celrep.2014.03.003 (2014).

Kovac, M. *et al*. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. *Nature communications* **6**, 8940, doi:10.1038/ncomms9940 (2015).

Glioma:

Bender, S. *et al*. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. *Nat. Med.*, doi:10.1038/nm.4204 (2016).

Jones, D. T. *et al*. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. *Nat. Genet.* **45**, 927-932, doi:10.1038/ng.2682 (2013).

Wu, G. *et al*. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. *Nat. Genet.* **44**, 251-253, doi:10.1038/ng.1102 (2012).

Wu, G. *et al*. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. *Nat. Genet.* **46**, 444-450, doi:10.1038/ng.2938 (2014).

Zhang, J. *et al*. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. *Nat. Genet.* **45**, 602-612, doi:10.1038/ng.2611 (2013).

Medulloblastoma:
Kool, M. *et al*. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell* **25**, 393-405, doi:10.1016/j.ccr.2014.02.004 (2014).
Northcott, P. A. *et al*. The whole-genome landscape of medulloblastoma subtypes. *Nature* **547**, 311-317, doi:10.1038/nature22973 (2017).
Robinson, G. *et al*. Novel mutations target distinct subgroups of medulloblastoma. *Nature* **488**, 43-48, doi:10.1038/nature11213 (2012).

Wilms' tumors:
Wegert, J. *et al*. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. *Cancer Cell* **27**, 298-311, doi:10.1016/j.ccell.2015.01.002 (2015).

ATRT:
Johann, P. D. *et al*. Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. *Cancer Cell* **29**, 379-393, doi:10.1016/j.ccell.2016.02.001 (2016).

ETMR:
Lambo *et al*., in preparation

Ependymoma:
Mack, S. C. *et al*. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. *Nature* **506**, 445-450, doi:10.1038/nature13108 (2014).
Parker, M. *et al*. C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. *Nature* **506**, 451-455, doi:10.1038/nature13109 (2014).

Neuroblastoma:
Cheung, N. K. *et al*. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. *Jama* **307**, 1062-1071, doi:10.1001/jama.2012.228 (2012).
Ackermann *et al*., in preparation

Adrenocortical carcinoma:
Pinto, E. M. *et al*. Genomic landscape of paediatric adrenocortical tumours. *Nature communications* **6**, 6302, doi:10.1038/ncomms7302 (2015).

Rhabdomyosarcoma:
Chen, X. *et al*. Targeting oxidative stress in embryonal rhabdomyosarcoma. *Cancer Cell* **24**, 710-724, doi:10.1016/j.ccr.2013.11.002 (2013).
Fulda *et al*., in preparation

Retinoblastoma:
Zhang, J. *et al*. A novel retinoblastoma therapy from genomic and epigenetic analyses. *Nature* **481**, 329-334, doi:10.1038/nature10733 (2012).
Temming *et al*., in preparation

Mixed:
Worst, B. C. *et al*. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. *Eur. J. Cancer* **65**, 91-101, doi:10.1016/j.ejca.2016.06.009 (2016).

Associated accession numbers:
European Nucleotide Archive: RP012816, PRJEB11430; European Genome Archive: EGAS00001001139, EGAS00001001953, EGAS00001000607, EGAS00001000381, EGAS00001000906, EGAS00001001297, EGAS00001000443, EGAS00001000213, EGAS00001000263, EGAS00001000192, EGAS00001000255, EGAS00001000254, EGAS00001000253, EGAS00001000256, EGAS00001000246, EGAS00001000379, EGAS00001000380, EGAS00001000346, EGAS00001000349, EGAS00001000347, EGAS00001000192